Metabolic disease is reshaping care delivery and costs, with experts at the Academy of Managed Care Pharmacy (AMCP) 2026 ...
Despite high rates of grade 3/4 infection, teclistamab was granted full approval by the FDA. Ajay K. Nooka, MD, speaks on how ...
The new report explained that the link between psoriasis and sleep disorders “is likely multifactorial, driven by ...
World Hemophilia Day spotlights the rare blood disorder that prevents the blood from clotting and can be dangerous when left ...
Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and ...
This analysis uses claims and electronic health records from 2021 to examine racial and ethnic variations in immune-mediated inflammatory diseases in the United States. Objectives: Few studies have ...
Ultimate disposition showed 54% approval (7% same-day; 47% after multiple days) and 46% denial, with 27% rejected within 1 ...
Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.
Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity ...
At AMCP 2026, Adam Colborn, JD, warns the Alternatives to PAIN Act may expand access but risk destabilizing Medicare Part D and limiting plan participation. The Academy of Managed Care Pharmacy (AMCP) ...
The Greater Philadelphia Business Coalition on Health will anchor a NACDD-selected 2026 regional summit to expand employer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results